Eli Lilly and

Yahoo Finance • 10 hours ago

Jim Cramer Highlights Elanco’s “Comeback Story”

Elanco Animal Health Incorporated (NYSE:ELAN) is one of the stocks Jim Cramer commented on. Cramer highlighted the stock’s terrific performance over the last 12 months, as he commented: I love a good comeback story. Right now, there’s a g... Full story

Yahoo Finance • 14 hours ago

Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says

Biogen's (BIIB) new Alzheimer's drug, BIIB080, has mid-year results coming up and its success is unc PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 15 hours ago

Eli Lilly Says Orforglipron Outperforms Oral Semaglutide in Phase 3 Trial

Eli Lilly (LLY) said Thursday its experimental oral GLP-1 receptor agonist orforglipron outperformed PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 16 hours ago

Jim Cramer Recommends Eli Lilly over Novo Nordisk

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Answering a caller’s question about the stock during the lightning round, Cramer said: Oh no, you don’t want to be in Novo Nordisk. You want to be in Eli Lilly. Nov... Full story

Yahoo Finance • 18 hours ago

Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

Soleno Therapeutics REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced t... Full story

Yahoo Finance • 18 hours ago

OTF + Lilly Collaboration Update on Registration Response | OMA QI Scaling Initiative Gains National Response, Bringing Together Diverse Practice Types Across 39 States

Denver, Colorado--(Newsfile Corp. - February 26, 2026) - The Obesity Medicine Association (OMA) is seeing strong early momentum for its Implementation into Practice Collaborative (IPC), a program designed to help clinicians strengthen obes... Full story

Yahoo Finance • 20 hours ago

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3 In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral... Full story

Yahoo Finance • yesterday

Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight

The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S(NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G)... Full story

Yahoo Finance • yesterday

Novo Nordisk Resets Obesity Strategy After CagriSema Miss And Vivtex Deal

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk's CagriSema weight loss drug missed its main target in a key phase 3 trial, falling s... Full story

Yahoo Finance • yesterday

NVIDIA Announces Financial Results for Fourth Quarter and Fiscal 2026

NVIDIA NVIDIA corporate headquartersNVIDIA corporate headquarters in Silicon Valley·GlobeNewswire Inc. Record quarterly revenue of $68.1 billion, up 20% from Q3 and up 73% from a year ago Record quarterly Data Center revenue of $62.3 bil... Full story

Yahoo Finance • 2 days ago

Novo Partners Vivtex in Deal Worth Up to $2.1 Billion

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) has moved to reinforce its long-term growth narrative, announcing a partnership with US biotech Vivtex Corp. that could be worth up to $2.1 billion as it seeks to expand it... Full story

Yahoo Finance • 2 days ago

Novo Nordisk Strikes Up to $2.1B Vivtex Deal for Oral Obesity Drugs

This article first appeared on GuruFocus. Novo Nordisk A/S (NVO, Financials) has agreed to a partnership worth up to $2.1 billion with Boston-based Vivtex Corporation to develop next-generation oral biologic therapies targeting obesity, d... Full story

Yahoo Finance • 2 days ago

Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 open-label extension study. The study is t... Full story

Yahoo Finance • 2 days ago

Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact

Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks.Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact On February 24, BofA said Novo Nordisk’s decision to... Full story

Yahoo Finance • 2 days ago

BofA sees limited impact to Eli Lilly’s franchise from Novo’s GLP-1 price update

BofA says that today’s announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm’s view the update is unlikely to have any material impact on the U.S. market. BofA sees today’s move as... Full story

Yahoo Finance • 2 days ago

Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie

Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development. Pharma stocks trade at about a 25% discount to their 10 year averages despite impr... Full story

Yahoo Finance • 2 days ago

Novo Nordisk's Loss Is Eli Lilly's Gain

Eli Lilly and Company(NYSE:LLY) shares are up on Monday as the company benefits from positive market sentiment following Novo Nordisk A/S’ (NYSE:NVO) disappointing trial results for a weight-loss drug, adding pressure as broader markets ed... Full story

Yahoo Finance • 3 days ago

Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly’s Zepbound

[New Nordisk] hapabapa/iStock Editorial via Getty Images J.P. Morgan downgraded Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) on Tuesday after the Danish drugmaker posted late-stage trial data indicating that its next-gen weigh... Full story

Yahoo Finance • 3 days ago

Personalized Medicine Market Competitive Landscape Report 2025: Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo Personalized Medicine Market Poised for Tremendous Growth by 2033The global personalized medicine market, valued at approximately US$ 585.53 billion in 2026, is projected to soar to nearly US$ 1.00 trillion by 2033. A report... Full story

Yahoo Finance • 3 days ago

Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound

Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound Proactive uses images sourced from Shutterstock The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's... Full story